Related Experiment Video
Updated: Nov 5, 2025

Protocol and Guidelines for Point-of-Care Lung Ultrasound in Diagnosing Neonatal Pulmonary Diseases Based on International Expert Consensus
Published on: March 6, 2019
Quality and consistency of clinical practice guidelines for treating children with COVID-19
Qinyuan Li1, Qi Zhou2,3, Yangqin Xun3
1Department of Respiratory Medicine Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing, China.
Insights
Clinical practice guidelines for pediatric Coronavirus Disease 2019 (COVID-19) treatment show low quality and inconsistent recommendations. Limited evidence from children hinders effective care guidance.
Area of Science:
- Pediatric Infectious Diseases
- Clinical Practice Guidelines
- Evidence-Based Medicine
Background:
- The Coronavirus Disease 2019 (COVID-19) pandemic significantly impacts children's health.
- Numerous clinical practice guidelines (CPGs) exist for pediatric COVID-19 treatment.
- The quality and consistency of these CPGs are largely unknown.
Purpose of the Study:
- To systematically review and evaluate the quality of existing CPGs for managing COVID-19 in children.
- To assess the methodological rigor and reporting completeness of pediatric COVID-19 CPGs.
- To analyze the consistency of treatment recommendations across guidelines.
Main Methods:
- Systematic literature search of databases (Medline, Embase) and guideline repositories.
- Evaluation of guideline quality using the Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool.
- Assessment of reporting completeness using the Reporting Items for practice Guidelines in HealThcare (RIGHT) checklist.
- Analysis of recommendation consistency and supporting evidence.
Main Results:
- Twenty pediatric COVID-19 CPGs were included.
- Methodological quality was predominantly low (95%), with only one moderate.
- Reporting quality was mostly moderate (60%), with one high-quality guideline.
- Significant inconsistencies were found in recommendations for treatments like remdesivir, interferon, glucocorticoids, and IVIG.
- None of the guidelines cited clinical trials involving pediatric COVID-19 patients.
Conclusions:
- Pediatric COVID-19 CPGs exhibit suboptimal methodological and reporting quality.
- Treatment recommendations vary widely among guidelines, indicating a lack of consensus.
- The evidence base derived from pediatric COVID-19 studies used in these guidelines is notably limited.
Background:
The Coronavirus Disease 2019 (COVID-19) pandemic negatively affects children's health. Many guidelines have been developed for treating children with COVID-19. The quality of the existing guidelines and the consistency of recommendations remains unknown. Therefore, we aim to review the clinical practice guidelines (CPGs) for children with COVID-19 systematically.
Methods:
We systematically searched Medline, Embase, guideline-related websites, and Google. The Appraisal of Guidelines for Research and Evaluation II (AGREE II) tool and Reporting Items for practice Guidelines in HealThcare (RIGHT) checklist were used to evaluate the methodological and reporting quality of the included guidelines, respectively. The consistency of recommendations across the guidelines and their supporting evidence were analyzed.
Results:
Twenty guidelines were included in this study. The mean AGREE II score and mean RIGHT reporting rate of the included guidelines were 37% (range, 22-62%) and 52% (range, 31-89%), respectively. As for methodological quality, no guideline was classified as high, one guideline (5%) moderate, and 19 (95%) low. In terms of reporting quality, one guideline (5%) was rated as high, 12 guidelines (60%) moderate, and seven (35%) low. Among included guidelines, recommendations varied greatly in the use of remdesivir (recommend: 25%, not recommend: 45%, not report: 30%), interferon (recommend: 15%, not recommend: 50%, not report: 35%), glucocorticoids (recommend: 50%, not recommend: 20%, not report: 30%), and intravenous immune globulin (recommend: 35%, not recommend: 30%, not report: 35%). None of the guidelines cited clinical trials from children with COVID-19.
Conclusions:
The methodological and reporting quality of guidelines for treating children with COVID-19 was not high. Recommendations were inconsistent across different guidelines. The supporting evidence from children with COVID-19 was very limited.
Related Concept Videos
Pharmacokinetics in Pediatric Patients: Drug Excretion
Standards of Care II
Standards of Care I
Standard Precaution
Hand hygiene is the most crucial means to prevent the transmission of disease. Employers are legally required to provide their workers with personal protective equipment (PPE) to minimize exposure or contact with...
Drug Dosing: Infants and Children
Asthma-IV: Diagnostic and Management
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

